Pixatimod

binds directly to the SARS-CoV-2 spike protein S1 receptor binding domain (RBD) and alters its conformation

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

PG545

Link	Tested on	Impact factor	Notes	Publication date
Pixatimod (PG545), a clinical-stage heparan sulfate mimetic, is a potent inhibitor of the SARS-CoV-2 virus Preprint	VERO E6 cell cultures			Jun/24/2020

Link	Publication date
Development of Improved Synthetic Routes to Pixatimod (PG545), a Sulfated Oligosaccharide-Steroid Conjugate.	Nov/12/2020
Structural insights into pixatimod (PG545) inhibition of heparanase, a key enzyme in cancer and viral infections.	May/01/2021